18
nanotimes
Companies Facts
b
itop AG, Germany, which specializes in the development and marketing of Ectoin®
-
containing medical devices, announces that Ectoin® significantly reduces nanoparticle-induced in- flammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease (COPD). It is the first time that Ectoin®
has been
shown to have such an effect on nanoparticle-indu- ced lung inflammation. Current therapy for COPD is treatment with glucocorticoids that, however, have only limited effect on nanoparticle-induced lung
inflammation even when inhaled. Carbon nanopar- ticles (CNPs), a well-accepted model for the carbo- naceous core of combustion-derived nanoparticles, induce lung inflammation in rats by causing an influx of neutrophil granulocytes into the lung epithelium. Ectoin®
, given locally with or before the application
of nanoparticles, reduced neutophil influx by about 30%. Furthermore, it prevented CNP-induced incre- ase in cinc-1 release.
http://www.bitop.de
10-05/06 :: May/June 2010
Advertisement
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83